The Journal of Neuropsychiatry and Clinical Neurosciences
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kim, E.
* Articles by Humaran, T. J.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Kim, E.
* Articles by Humaran, T. J.
J Neuropsychiatry Clin Neurosci 14:202-205, May 2002
© 2002 American Psychiatric Press, Inc.


Clinical and Research Reports

Divalproex in the Management of Neuropsychiatric Complications of Remote Acquired Brain Injury

Edward Kim, M.D. and Teresa J. Humaran, M.D.

Received November 17, 2000; revised March 20, 2001; accepted March 26, 2001. From the Department of Psychiatry, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ 08855-1392. Address correspondence to Dr. Kim. E-mail: kimed{at}cmhc.umdnj.edu

ABSTRACT

A retrospective chart review was conducted on 11 patients with a remote history of acquired brain injury (ABI) referred for psychiatric treatment who were treated with divalproex sodium alone or in combination with other psychotropic medications. The patients were highly heterogeneous. They had a variety of psychiatric symptoms and frequently received concomitant psychotropic medications. The mean daily dose of divalproex was 1,818±791 mg/day, serum valproic acid level 85.6±29.6 µg/ml. Mean Clinical Global Impression improvement score was 1.9±0.5. This is the largest postacute case series reported. It demonstrates that divalproex sodium is well tolerated and effective in reducing a broad range of neurobehavioral symptoms in psychiatric patients with a remote history of ABI.

Key Words: Brain Injury • Divalproex • Agitation




This article has been cited by other articles:


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
D. R. Spiegel, J. Burgess, D. Samuels, R. Laroia, and S. Kirshenbaum
Disinhibition Due to Disruption of the Orbitofrontal Circuit Treated Successfully With Carbamazepine: A Case Series
J Neuropsychiatry Clin Neurosci, August 1, 2009; 21(3): 323 - 327.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
S. F. Handel, L. Ovitt, J. R. Spiro, and V. Rao
Affective Disorder and Personality Change in a Patient With Traumatic Brain Injury
Psychosomatics, February 1, 2007; 48(1): 67 - 70.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2002 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Neuropsychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org